Clinical Trials Logo

Clinical Trial Summary

The study compares the efficacy and safety of modified release prednisone versus immediate release prednisone in patients suffering from polymyalgia rheumatica.


Clinical Trial Description

The study consists of a screening phase, followed by a 4 week double-blind phase. During the double-blind phase, the patients will be randomised in a 1:1 ratio to either Lodotra® or immediate release prednisone (prednisone IR) plus respective placebo.

After completion of the double-blind phase, patients will be re-randomised in a 1:1 ratio to open-label Lodotra® or prednisone IR for 48 weeks. During the open-label phase, the dose of study medication will be tapered based on titration criteria. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01821040
Study type Interventional
Source Mundipharma Research Limited
Contact
Status Terminated
Phase Phase 3
Start date March 2013
Completion date April 2014

See also
  Status Clinical Trial Phase
Terminated NCT04972968 - A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment, Receiving Subcutaneous Injections of ABBV-154 Phase 2
Active, not recruiting NCT04519580 - Improved Diagnostics and Monitoring of Polymyalgia Rheumatica
Terminated NCT03600818 - Evaluation of the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica Phase 3
Completed NCT00836810 - Timed Release Tablet Prednisone in Polymyalgia Rheumatica Phase 2/Phase 3
Completed NCT04239521 - The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
Completed NCT03263715 - A Study to Evaluate the Efficacy of Tocilizumab as a Remission-Induction and Glucocorticoid-Sparing Regimen in Subjects With New-Onset Polymyalgia Rheumatica (PMR- SPARE) Phase 3
Recruiting NCT05935709 - DANIsh VASculitis Database (DANIVAS)
Not yet recruiting NCT02985424 - Polymyalgia Rheumatica and Giant Cell Arteritis N/A
Completed NCT00138983 - Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol. Phase 3
Recruiting NCT06130540 - Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR Phase 1
Recruiting NCT05767034 - Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR) Phase 3
Recruiting NCT00982332 - Efficacy of Micro-Pulse Steroid Therapy as Induction Therapy in Patients With Polymyalgia Rheumatica N/A
Recruiting NCT05312944 - Polymyalgia Rheumatica Associated to Primary Sjogren Syndrome
Recruiting NCT04664465 - PRediction Of DIverse Glucocorticoids toxIcity OUtcomeS
Withdrawn NCT02899026 - Efficacy and Safety Study of Sirukumab in Subjects With Polymyalgia Rheumatica Phase 3
Not yet recruiting NCT06281236 - A Trial of Prednisolone in Combination With SPI-62 in Participants With Polymyalgia Rheumatica (PMR) Phase 1
Recruiting NCT03576794 - Treatment With Leflunomide in Patients With Polymyalgia Rheumatica Phase 3
Completed NCT05681676 - Melanocortin Gene Expression in Lymphocytes of Polymyalgia Patients
Recruiting NCT05435781 - Effect of Supplemental Hydrocortisone During Stress in Prednisolone-induced Adrenal Insufficiency Phase 4
Terminated NCT03656627 - Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease Phase 1